Phosphodiesterase-5 (PDE5) inhibitors, commonly used for erectile dysfunction and pulmonary arterial hypertension, are emerging as potential candidates for repurposing in diabetes management due to their favourable safety profile and potential cardiovascular benefits. The gene discussed is PDE5A; the disease is erectile dysfunction.